Serum levels of the Th1 promoter IL-12 and the Th2 chemokine TARC are elevated in erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis and correlate with soluble fas ligand expression: An immunoenzymatic study from the Italian group of immunopathology

Dermatology

Volumn 214, Issue 4, 2007, Pages 296-304

  Quaglino, Pietro ^a   Caproni, Marzia ^b   Antiga, Emiliano ^b   Del Bianco, Elena ^b   Osella Abate, Simona ^a   Savoia, Paola ^a   Frezzolini, Alessandra ^c   Schena, Donatella ^d   Marzano, Angelo ^e   Volpi, Walter ^b   De Simone, Clara ^c   Parodi, Aurora ^f   Fabbri, Paolo ^b   Bernengo, Maria Grazia ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

Author keywords

Erythema multiforme; Stevens Johnson syndrome toxic epidermal necrolysis; Thymus and activation regulated chemokine

Indexed keywords

CHEMOKINE; FAS LIGAND; INTERLEUKIN 12; MACROPHAGE DERIVED CHEMOKINE; RANTES; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA MULTIFORME; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STEVENS JOHNSON SYNDROME; TH1 CELL; TH2 CELL; TOXIC EPIDERMAL NECROLYSIS; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHEMOKINES; CHEMOKINES, CC; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMAL NECROLYSIS, TOXIC; ERYTHEMA MULTIFORME; FAS LIGAND PROTEIN; FEMALE; HUMANS; INTERLEUKIN-12; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANTES; STEVENS-JOHNSON SYNDROME; TH1 CELLS; TH2 CELLS;

EID: 34247548710     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100880     Document Type: Article

References (56)

1. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC: Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-96.
2. Roujeau JC: The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994;102:28S-30S.
3. Roujeau JC: Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997;24:726-729.
4. Assier H, Bastuji-Garin S, Revuz J, Roujeau JC: Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 1995;131:539-543.
5. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC; SCAR Study Group: Severe Cutaneous Adverse Reactions: Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002;138:1019-1024.
6. Paquet P, Pierard GE: Erythema multiforme and toxic epidermal necrolysis: a comparative study. Am J Dermatopathol 1997;19:127-132.
7. Paquet P, Paquet F, Al Saleh W, Reper P, Vanderkelen A, Pierard GE: Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis. Am J Dermatopathol 2000;22:413-417.
8. Cote B, Wechsler J, Bastuji-Garin S, Assier H, Revuz J, Roujeau JC: Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol 1995;131:1268-1272.
9. Aurelian L, Ono F, Burnett J: Herpes simplex virus (HSV)-associated erythema multiforme (HAEM): a viral disease with an autoimmune component. Dermatol Online J 2003;9:1.
10. Correia O, Delgado L, Barbosa IL, Campilho F, Fleming-Torrinha J: Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol 2002;47:58-62.
11. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H: Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003;162:1515-1520.
12. Posadas SJ, Padial A, Torres MJ, Mayorga C, Leyva L, Sanchez E, Alvarez J, Romano A, Juarez C, Blanca M: Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002;109:155-161.
13. Posadas SJ, Torres MJ, Mayorga C, Juarez C, Blanca M: Gene expression levels of cytokine profile and cytotoxic markers in non-immediate reactions to drugs. Blood Cells Mol Dis 2002;29:179-189.
14. Nassif A, Moslehi H, Le Gouvello S, Bagot M, Lyonnet L, Michel L, Boumsell L, Bensussan A, Roujeau JC: Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004;123:850-855.
15. Hertl M, Geisel J, Boecker C, Merk HF: Selective generation of CD8+ T-cell clones from the peripheral blood of patients with cutaneous reactions to beta-lactam antibiotics. Br J Dermatol 1993;128:619-626.
16. Posadas SJ, Leyva L, Torres MJ, Rodriguez JL, Bravo I, Rosal M, Fernandez J, Juarez C, Blanca M: Subjects with allergic reactions to drugs show in vivo polarized patterns of cytokine expression depending on the chronology of the clinical reaction. J Allergy Clin Immunol 2000;106:769-776.
17. Kokuba H, Aurelian L, Burnett J: Herpes simplex virus associated erythema multiforme (HAEM) is mechanistically distinct from drug-induced erythema multiforme: interferon-gamma is expressed in HAEM lesions and tumor necrosis factor-alpha in drug-induced erythema multiforme lesions. J Invest Dermatol 1999;113:808-815.
18. Brugnolo F, Annunziato F, Sampognaro S, Campi P, Manfredi M, Matucci A, Blanca M, Romagnani S, Maggi E, Parronchi P: Highly Th2-skewed cytokine profile of beta-lactam-specific T cells from non-atopic subjects with adverse drug reactions. J Immunol 1999;163:1053-1059.
19. Correia O, Delgado L, Roujeau JC, Le Cleach L, Fleming-Torrinha JA: Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples. Arch Dermatol 2002;138:29-32.
20. Teraki Y, Kokaji T, Shiohara T. Expansion of IL-10-producing CD4+ and CD8+ T cells in fixed drug eruption. Dermatology 2006;213:83-87.
21. Caproni M, Torchia D, Schincaglia E, Volpi W, Frezzolini A, Schena D, Marzano A, Quaglino P, De Simone C, Parodi A, Barletta E, Fabbri P: Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 2006;155:722-728.
22. Mackay CR: Chemokines: immunology's high impact factors. Nat Immunol 2001;2:95-101.
23. Baggiolini M, Loetscher P: Chemokines in inflammation and immunity. Immunol Today 2000;21:418-420.
24. Sallusto F, Lanzavecchia A, Mackay CR: Chemokines and chemokine receptors in Tcell priming and Th1/Th2-mediated responses. Immunol Today 1998;19:568-574.
25. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F: Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998;187:129-134.
26. Imai T, Chantry D, Raport CJ, Wood CL, Nishimura M, Godiska R, Yoshie O, Gray PW: Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4. J Biol Chem 1998;273:1764-1768.
27. Godiska R, Chantry D, Raport CJ, Sozzani S, Allavena P, Leviten D, Mantovani A, Gray PW: Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med 1997;185:1595-1604.
28. Appay V, Rowland-Jones SL: RANTES: a versatile and controversial chemokine. Trends Immunol 2001;22:83-87.
29. Fahy O, Porte H, Senechal S, Vorng H, McEuen AR, Buckley MG, Walls AF, Wallaert B, Tonnel AB, Tsicopoulos A: Chemokine-induced cutaneous inflammatory cell infiltration in a model of Hu-PBMC-SCID mice grafted with human skin. Am J Pathol 2001;158:1053-1063.
30. Spandau U, Brocker EB, Kampgen E, Gillitzer R: CC and CXC chemokines are differentially expressed in erythema multiforme in vivo. Arch Dermatol 2002;138:1027-1033.
31. Tapia B, Padial A, Sanchez-Sabate E, Alvarez-Ferreira J, Morel E, Blanca M, Bellon T: Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions. J Allergy Clin Immunol 2004;114:335-340.
32. Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ: IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004;202:96-105.
33. Sayama K, Yonehara S, Watanabe Y, Miki Y: Expression of Fas antigen on keratinocytes in vivo and induction of apoptosis in cultured keratinocytes. J Invest Dermatol 1994;103:330-334.
34. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S: Fas ligand in human serum. Nat Med 1996;2:317-322.
35. Becker C, Wirtz S, Neurath MF: Stepwise regulation of TH1 responses in autoimmunity: IL-12-related cytokines and their receptors. Inflamm Bowel Dis 2005;11:755-764.
36. Caproni M, Torchia D, Schincaglia E, Volpi W, Frezzolini A, Schena D, Marzano A, Quaglino P, De Simone C, Parodi A, Barletta E, Fabbri P: The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Br J Dermatol 2006;154:319-324.
37. Caproni M, Antiga E, Parodi A, Schena D, Marzano A, Quaglino P, De Simone C, La Placa M, Volpi W, Del Bianco E, Fabbri P: Elevated circulating CD40 ligand in patients with erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Br J Dermatol 2006;154:1006-1007.
38. Shu U, Kiniwa M, Wu CY, Maliszewski C, Vezzio N, Hakimi J, Gately M, Delespesse G: Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur J Immunol 1995;25:1125-1128.
39. Peng X, Remacle JE, Kasran A, Huylebroeck D, Ceuppens JL: IL-12 up-regulates CD40 ligand (CD154) expression on human T cells. J Immunol 1998;160:1166-1172.
40. Saeki H, Tamaki K: Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. J Dermatol Sci 2006;43:75-84.
41. Sebastiani S, Albanesi C, Nasorri F, Girolomoni G, Cavani A: Nickel-specific CD4+ and CD8+ T cells display distinct migratory responses to chemokines produced during allergic contact dermatitis. J Invest Dermatol 2002;118:1052-1058.
42. Vestergaard C, Deleuran M, Gesser B, Larsen CG: Thymus- and activation-regulated chemokine (TARC/CCL17) induces a Th2-dominated inflammatory reaction on intradermal injection in mice. Exp Dermatol 2004;13:265-271.
43. Horikawa T, Nakayama T, Hikita I, Yamada H, Fujisawa R, Bito T, Harada S, Fukunaga A, Chantry D, Gray PW, Morita A, Suzuki R, Tezuka T, Ichihashi M, Yoshie O: IFN-gamma-inducible expression of thymus and activation-regulated chemokine/CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis. Int Immunol 2002;14:767-773.
44. Albanesi C, Scarponi C, Sebastiani S, Cavani A, Federici M, Sozzani S, Girolomoni G: A cytokine-to-chemokine axis between T lymphocytes and keratinocytes can favor Th1 cell accumulation in chronic inflammatory skin diseases. J Leukoc Biol 2001;70:617-623.
45. Zheng X, Nakamura K, Tojo M, Akiba H, Oyama N, Nishibu A, Kaneko F, Tsunemi Y, Kakinuma T, Saeki H, Tamaki K: Ultraviolet A irradiation inhibits thymus and activation-regulated chemokine (TARC/CCL17) production by a human keratinocyte HaCaT cell line. Eur J Dermatol 2003;13:348-353.
46. Tsuda T, Tohyama M, Yamasaki K, Shirakata Y, Yahata Y, Tokumaru S, Sayama K, Hashimoto K: Lack of evidence for TARC/CCL17 production by normal human keratinocytes in vitro. J Dermatol Sci 2003;31:37-42.
47. Vulcano M, Albanesi C, Stoppacciaro A, Bagnati R, D'Amico G, Struyf S, Transidico P, Bonecchi R, Del Prete A, Allavena P, Ruco LP, Chiabrando C, Girolomoni G, Mantovani A, Sozzani S: Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur J Immunol 2001;31:812-822.
48. Vissers JL, Hartgers FC, Lindhout E, Teunissen MB, Figdor CG, Adema GJ: Quantitative analysis of chemokine expression by dendritic cell subsets in vitro and in vivo. J Leukoc Biol 2001;69:785-793.
49. Fukuda K, Fujitsu Y, Seki K, Kumagai N, Nishida T: Differential expression of thymus-and activation-regulated chemokine (CCL17) and macrophage-derived chemokine (CCL22) by human fibroblasts from cornea, skin, and lung. J Allergy Clin Immunol 2003;111:520-526.
50. Sekiya T, Yamada H, Yamaguchi M, Yamamoto K, Ishii A, Yoshie O, Sano Y, Morita A, Matsushima K, Hirai K: Increased levels of a TH2-type CC chemokine thymus and activation-regulated chemokine (TARC) in serum and induced sputum of asthmatics. Allergy 2002;57:173-177.
51. Yamagami S, Ebihara N, Amano SY: Chemokine receptor gene expression in giant papillae of atopic keratoconjunctivitis. Mol Vis 2005;11:192-200.
52. Trautmann A, Akdis M, Kleemann D, Altznauer F, Simon HU, Graeve T, Noll M, Brocker EB, Blaser K, Akdis CA: T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest 2000;106:25-35.
53. Fan H, Walters CS, Dunston GM, Tackey R: IL-12 plays a significant role in the apoptosis of human T cells in the absence of antigenic stimulation. Cytokine 2002;19:126-137.
54. Berthou C, Michel L, Soulie A, Jean-Louis F, Flageul B, Dubertret L, Sigaux F, Zhang Y, Sasportes M: Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defense. J Immunol 1997;159:5293-5300.
55. Guo Z, Zhang M, Tang H, Cao X: Fas signal links innate and adaptive immunity by promoting dendritic-cell secretion of CC and CXC chemokines. Blood 2005;106:2033-2041.
56. Fujisawa T, Fujisawa R, Kato Y, Nakayama T, Morita A, Katsumata H, Nishimori H, Iguchi K, Kamiya H, Gray PW, Chantry D, Suzuki R, Yoshie O: Presence of high contents of thymus and activation-regulated chemokine in platelets and elevated plasma levels of thymus and activation-regulated chemokine and macrophage-derived chemokine in patients with atopic dermatitis. J Allergy Clin Immunol 2002;110:139-146.